The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: Randomize into aTTom
- 31 December 1997
- journal article
- editorial
- Published by Elsevier in Clinical Oncology
- Vol. 9 (3), 141-143
- https://doi.org/10.1016/s0936-6555(97)80067-2
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Postchemotherapy Adjuvant Tamoxifen Therapy Beyond Five Years in Patients With Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive TumorsJNCI Journal of the National Cancer Institute, 1996
- Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancerBritish Journal of Cancer, 1996
- Risk of endometrial cancer after tamoxifen treatment of breast cancerThe Lancet, 1994
- The Royal Marsden Hospital pilot tamoxifen chemoprevention trialBreast Cancer Research and Treatment, 1994
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Potential Role of Tamoxifen in Prevention of Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.BMJ, 1991